METHOCARBAMOL

Post-LOE

methocarbamol

Baxter

ANDAORALTABLET

Approved

Jun 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

METHOCARBAMOL (methocarbamol) by Baxter is clinical pharmacology the mechanism of action of methocarbamol in humans has not been established, but may be due to general cns depression. First approved in 2023.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY The mechanism of action of methocarbamol in humans has not been established, but may be due to general CNS depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber. Pharmacokinetics In healthy volunteers, the…

Pharmacologic Class:

Muscle Relaxant

Indications

Worked on METHOCARBAMOL at Baxter? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.